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Abstract 
The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has 
intensified efforts to discover novel drugs for tuberculosis (TB) treatment. Targeting the 
persistent state of Mtb, a condition in which Mtb is resistant to conventional drug therapies, is of 
particular interest. Persistent bacterial population relies on metabolic pathways that become 
active in low nutrient environment like glyoxylate shunt. Since the glyoxylate shunt enzymes are 
not present in mammals, they make attractive drug targets. This study is focused on malate 
synthase (MS), one of the enzymes in the glyoxylate shunt. Computational approach was used to 
identify potential inhibitors of MS. Crystal structure of MS (PDB ID-1N8I) in complex with 
inhibitor was used to rationally design better MS inhibitors. PKBA is identified to be potent 
inhibitor of malate synthase enzyme. 30 molecules were designed based on malate (product of 
Malate Synthase) and Phenyl keto butanoic acid (PKBA) backbone. All molecules were screened 
based on the lowest energy with repeated conformation of ligands, and passed through 
ADME/tox filters to sort out the toxic compounds.  Molecular docking of all designed molecules 
with the receptor protein (malate synthase) was performed. The binding energy and inhibitory 
concentration was observed. On the basis of this study, the best molecule having the lowest 
binding energy and inhibitory concentration was identified. The best molecule identified was 
further evaluated by molecular dynamics simulation of protein-ligand complex in water solvent 
model. The rmsd close to 2 A◦ shows the stability of the complex. Inhibitors against MS have 
been identified and characterized for further development into potential novel anti-tubercular 
drugs. 
 
Keywords: Mycobacterium tuberculosis, Malate Synthase (MS), Phenyl-Keto Butanoic Acid 
(PKBA), ADME/tox, Molecular dynamics simulation. 
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Introduction: 
Biology has traditionally been an observational rather than a deductive science. Although recent 
developments have not altered this basic orientation, the nature of the data has radically changed. 
It is arguable that until recently all biological observations were fundamentally anecdotal - 
admittedly with varying degrees of precision, some very high indeed. However, in the last 
generation the data have become not only much more quantitative and precise, but, in the case of 
nucleotide and amino acid sequences, they have become discrete. It is possible to determine the 
genome sequence of an individual organism or clone not only completely, but in principle 
exactly. Experimental error can never be avoided entirely, but for modern genomic sequencing it 
is extremely low. 
Not that this has converted biology into a deductive science. Life does obey principles of physics 
and chemistry, but for now life is too complex, and too dependent on historical contingency, for 
us to deduce its detailed properties from basic principles. 
A second obvious property of the data of bioinformatics is their very very large amount. 
Currently the nucleotide sequence databanks contain 16 × 109 bases (abbreviated 16 Gbp). If we 
use the approximate size of the human genome - 3.2 × 109 letters - as a unit, this amounts to five 
HUman Genome Equivalents (or 2 huges, an apt name). The database of macromolecular 
structures contains 16 000 entries, the full three-dimensional coordinates of proteins, of average 
length ~400 residues. Not only are the individual databanks large, but their sizes are increasing at 
a very high rate. It appears that the ability to generate vast quantities of data has surpassed the 
ability to use this data meaningfully. The pharmaceutical industry has embraced genomics as a 
source of drug targets. It also recognizes that the field of bioinformatics is crucial for validating 
these potential drug targets and for determining which ones are the most suitable for entering the 
drug development pipeline. 
Recently, there has been a change in the way that medicines are being developed due to our 
increased understanding of molecular biology. In the past, new synthetic organic molecules were 
tested in animals or in whole organ preparations. This has been replaced with a molecular target 
approach in which in-vitro screening of compounds against purified, recombinant proteins or 
genetically modified cell lines is carried out with a high throughput. This change has come about 
as a consequence of better and ever improving knowledge of the molecular basis of disease. All 
this has been possible because of knowledge of bioinformatics. 
Drugs work by interacting with target molecules (receptors) in our bodies and altering their 
activities in a way that is beneficial to our health. In some cases, the effect of a drug is to 
stimulate the activity of its target (an agonist) while in other cases the drug blocks the activity of 
its target (an antagonist). Finding effective drugs is difficult. Many are discovered by chance 
observations, the scientific analysis of folk medicines or by noting side effects of other drugs. A 
more systematic method is large-scale screening experiments where potential drug targets are 
tested with thousands of different compounds to see if interactions take place. 
Drug design is the inventive process of finding new medications based on the knowledge of the 
biological target [37]. The drug is most commonly a organic small molecule which activates or 
inhibits the function of a biomolecule such as a protein which in turn results in a therapeutic 
benefit to the patient. In the most basic sense, drug design involves finding small molecules that 
are complementary in shape and charge to the biomolecular target to which they interact. Drug 
design frequently but not necessarily relies on computer modeling techniques [37]. This type of 
modeling often referred to as computer-aided drug design. 
Rational Drug Discovery (RDD). In contrast to traditional methods of drug discovery which rely 
on trial-and-error testing of chemical substances on cultured cells or animals, and matching the 
apparent effects to treatments, rational drug design begins with a hypothesis that modulation of a 
specific biological target may have therapeutic value. It is a more focused approach, which uses 
information about the structure of a drug receptor or one of its natural ligands to identify or 
create candidate drugs. The three-dimensional structure of a protein can be determined using 
methods such as X-ray crystallography or nuclear magnetic resonance spectroscopy. Armed with 
this information, researchers in the pharmaceutical industry can use powerful computer 
programmes to search through databases containing the structures of many different chemical 
compounds. The computer can select those compounds that are most likely to interact with the 
receptor, and these can be tested in the laboratory. If an interacting compound cannot be found in 
this manner, other programmes can be used that attempt, from first principles, to build molecules 
that are likely to interact with the receptor. Further programmes can search databases to identify 
compounds with similar properties to known ligands. The idea is to narrow down the search as 
much as possible to avoid the expense of large-scale screening. The first drug produced by 
rational design was Relenza, which is used to treat influenza. Relenza was developed by 
choosing molecules that were most likely to interact with neuraminidase, a virus-produced 
enzyme that is required to release newly formed viruses from infected cells. 
Structure-Based Drug Design (SBDD). Structure-based drug design is one of several methods in 
the rational drug design toolbox. Drug targets are typically key molecules involved in a specific 
metabolic or cell signaling pathway that is known, or believed, to be related to a particular 
disease state. Drug targets are most often proteins and enzymes in these pathways. Drug 
compounds are designed to inhibit, restore or otherwise modify the structure and behavior of 
disease-related proteins and enzymes. SBDD uses the known 3D geometrical shape or structure 
of proteins to assist in the development of new drug compounds. Using the structure of the 
biological target, candidate drugs that are predicted to bind with high affinity and selectivity to 
the target may be designed using interactive graphics and the intuition of a medicinal chemist. 
Alternatively various automated computational procedures may be used to suggest new drug 
candidates. The 3D structure of protein targets is most often derived from x-ray crystallography 
or nuclear magnetic resonance (NMR) techniques. X-ray and NMR methods can resolve the 
structure of proteins to a resolution of a few angstroms (about 500,000 times smaller than the 
diameter of a human hair). At this level of resolution, researchers can precisely examine the 
interactions between atoms in protein targets and atoms in potential drug compounds that bind to 
the proteins. This ability to work at high resolution with both proteins and drug compounds 
makes SBDD one of the most powerful methods in drug design.  
In-silico Drug Design. In silico methods can help in identifying drug targets via bioinformatics 
tools. They can also be used to analyze the target structures for possible binding/ active sites, 
generate candidate molecules, check for their drug likeness, dock these molecules with the target 
, rank them according to their binding affinities , further optimize the molecules to improve 
binding characteristics 
The use of computers and computational methods permeates all aspects of drug discovery today 
and forms the core of structure-based drug design. High-performance computing, data 
management software and internet are facilitating the access of huge amount of data generated 
and transforming the massive complex biological data into workable knowledge in modern day 
drug discovery process. The use of complementary experimental and informatics techniques 
increases the chance of success in many stages of the discovery process, from the identification 
of novel targets and elucidation of their functions to the discovery and development of lead 
compounds with desired properties. Computational tools offer the advantage of delivering new 
drug candidates more quickly and at a lower cost. Major roles of computation in drug discovery 
are; (1) Virtual screening & de novo design, (2) in silico ADME/T prediction and (3) Advanced 
methods for determining protein-ligand binding. 
Why in-silico Drug Design is significant? As structures of more and more protein targets become 
available through crystallography, NMR and bioinformatics methods, there is an increasing 
demand for computational tools that can identify and analyze active sites and suggest potential 
drug molecules that can bind to these sites specifically. Also to combat life-threatening diseases 
such as AIDS, Tuberculosis, Malaria etc., a global push is essential. Millions for Viagra and 
pennies for the diseases of the poor is the current situation of investment in Pharma R&D. Time 
and cost required for designing a new drug are immense and at an unacceptable level. According 
to some estimates it costs about $880 million and 14 years of research to develop a new drug 
before it is introduced in the market Intervention of computers at some plausible steps is 
imperative to bring down the cost and time required in the drug discovery process. The journey 
of development of a new drug from diseases to drug follows the following path: 
Which Disease to Study? One needs to study thoroughly to select a disease which can be 
targeted. The disease can be selected based on different criteria like past experience on same or 
similar disease or the emerging disease can be selected for which drugs are not available or for 
which the available drugs are not very effective. Selection can also be made on the basis of cost 
of treatment for the disease or for which available drugs have side effects. Also, disease can be 
selected where etiology is not understood at molecular level. 
Understanding the disease Process: One needs to understand the etiology of a disease 
thoroughly before selecting a drug target whether the disease is caused by pathogen invasion or 
due to over production of cells, under production of cells or due to degeneration of cells. The 
disease can be studied based on prior knowledge stored in different literature database or based 
on experimental studies like pedigree analysis, Gene Cloning, DNA arrays. 
Target Selection: The target selection should be made carefully. In order for a biomolecule to be 
selected as a drug target, two essential pieces of information are required. The first is evidence 
that modulation of the target will have therapeutic value. This knowledge may come from, for 
example, disease linkage studies that show an association between mutations in the biological 
target and certain disease states. The second is that the target is "drugable". This means that it is 
capable of binding to a small molecule and that its activity can be modulated by the small 
molecule. Among all biomolecules, proteins are the most successful targets. Target should be 
validated by different experimental methods like gene knockout study or using RNA anti-sense 
technology. Once a suitable target has been identified, the target is normally cloned and 
expressed. The expressed target is then used to establish a screening assay. In addition, the three-
dimensional structure of the target may be determined. 
Search for Lead Molecules: The search for small molecules that bind to the target is begun by 
screening libraries of potential drug compounds. This may be done by using the screening assay 
(a "wet screen"). In addition, if the structure of the target is available, a virtual screen may be 
preformed of candidate drugs. Ideally the candidate drug compounds should be "drug-like", that 
is they should possess properties that are predicted to lead to oral bioavailability, adequate 
chemical and metabolic stability, and minimal toxic effects. One way of estimating drug likeness 
is Lipinski's Rule of Five. Several methods for predicting drug metabolism have been proposed 
in the scientific literature, and a recent example is SPORCalc [37]. Due to the complexity of the 
drug design process, two terms of interest are still serendipity and bounded rationality. Those 
challenges are caused by the large chemical space describing potential new drugs without side-
effects. 
Understanding the molecular basis for disease: Many drugs are small ligand molecules that 
interact with macromolecular surfaces. Affinity and specificity of ligand binding are determined 
by molecular surface patterns, their chemical similarity and structural complementarity, and 
governed by non-covalent bonds that are electrostatic in nature. Our understanding of biological 
ligand-receptor systems leads the way to applications in the drug discovery process and the 
successful design of efficient, specific, and non-toxic small-molecule therapeutics. 
Refine Drug Activity: Once a number of lead compounds have been found, computational and 
laboratory techniques have been very successful in refining the molecular structures to give a 
greater drug activity and fewer side effects. This is done both in the laboratory and 
computationally by examining the molecular structures to determine which aspects are 
responsible for both the drug activity and the side effects.  
Synthetically, functional groups are removed in order to find out which must be present to give a 
useful drug and which are not necessary. The back bone of the structure is made more flexible or 
more rigid. A rigid back bone may hold the functional groups in the exact alignment necessary 
for the drug to bind. A flexible back bone may be necessary to allow the drug to get into the 
binding site. Adding bulky groups at other points on the molecule is often done in the hopes that 
these new groups may hinder the molecule from binding at unwanted sites which are responsible 
for the side effects. 
Computationally, the technique used is known as QSAR (Quantitative Structure Activity 
Relationships). It consists of computing every possible number that can describe a molecule then 
doing an enormous curve fit to find out which aspects of the molecule correlate well with the 
drug activity or side effect severity. This information can then be used to suggest new chemical 
modifications for synthesis and testing. 
Solubility of Molecule: Another important aspect of the molecular structure is its solubility. 
Whether the molecule is water soluble or readily soluble in fatty tissue will affect what part of 
the body it becomes concentrated in. The ability to get a drug to the correct part of the body is an 
important factor in its potency. 
Ideally there is a continual exchange of information between the researchers doing QSAR 
studies, synthesis and testing. These techniques are frequently used and often very successful 
since they do not rely on knowing the biological basis of the disease which can be very difficult 
to determine. 
Drug Testing: Once a drug has been shown to be effective by an initial assay technique, much 
more testing must be done before it can be given to human patients. Animal testing is the 
primary type of testing at this stage. The scientists doing the testing must be particularly 
observant of many little details since this is where unexpected side effects can be found. Another 
question to be answered is whether the drug will work well or poorly with other drugs. This is 
also where initial data necessary to determine correct dosages is obtained. Eventually, the 
compounds which are deemed suitable at this stage are sent on to clinical trials. In the clinical 
trials, additional side effects may be found and human dosages are determined. 
Motivation for the study: Tuberculosis (TB) is a deadly infectious disease and is the leading 
cause of death worldwide, killing around 2 million people annually, primarily in developing 
countries. The World Health Organization (WHO) estimates that over one third of the world’s 
population is infected with TB with approximately 8 million new cases of infection diagnosed 
every year [1]. After human immunodeficiency virus (HIV)/AIDS, TB is the second most 
common cause of death due to an infectious disease, and current trends suggest that TB will still 
be among the 10 leading causes of global disease burden in the year 2020[2].TB incidence is also 
on the rise because of the correspondingly high HIV infection rates. These two diseases progress 
at faster rates in co-infected individuals. The immune systems have been compromised by 
HIV/AIDS, so individuals fall victims to TB which takes opportunity of their weakened immune 
systems. There is a great interest in the scientific field to come up with a new drug(s) to combat 
TB. Tuberculosis is an airborne infectious disease caused by mycobacteria, mainly 
Mycobacterium tuberculosis (Mtb) [17]. The success of mycobacteria in producing disease relies 
entirely on its ability to utilize macrophages for its replication and more importantly, the 
maintenance of viability of host macrophages that sustain mycobacteria. M. tuberculosis has 
evolved several mechanisms to circumvent the hostile environment of the macrophage, its 
primary host cell. In spite of extensive research, our knowledge about the virulence factor(s) of 
M. tuberculosis is inadequate. A variety of mechanisms have been suggested to contribute 
towards the survival of mycobacteria within macrophages. These mechanisms include (i) 
inhibition of phagosome-lysosome fusion [12]; (ii) inhibition of phagosome acidification [13]; 
(iii) recruitment and retention of tryptophan/aspartate containing coat protein on phagosomes to 
prevent their delivery to lysosomes[14]; and (iv) host induced expression of members of the PE-
PGRS family of proteins[15]. 
Objective of the Study: Current TB therapy, also known as DOTS (directly observed treatment, 
short-course) is world-widely used for the treatment of tuberculosis but due to the emergence of 
multi drug resistant tuberculosis (MDR-TB) and association between HIV and TB, DOTS is 
becoming rapidly ineffective in controlling tuberculosis[18]. Recent reports indicate that, areas 
where there is a high incidence of MDR-TB, DOTS is failing to control the disease. One major 
drawback of current TB therapy is that the drugs are administered for at least 6 months. The 
length of therapy makes patient compliance difficult, and such patients become potent source of 
drug-resistant strains. The second major and serious problem of current therapy is that most of the 
TB drugs available today are ineffective against persistent bacilli, except for RIF and PZA. 
However, there are still persistent bacterial populations that are not killed by any of the available 
TB drugs. Therefore, there is a need to design new drugs that are more active against slowly 
growing or non-growing persistent bacilli to treat the population at risk of developing active 
disease through reactivation. Secondly, it is important to achieve a shortened therapy schedule to 
encourage patient’s compliance and to slow down the development of drug resistance in 
mycobacteria. To overcome these problems we have used, non conventional   methods of   drug 
designing namely Rational Drug Design (RDD) approach which can speedup of the drug 
designing process. RDD uses a variety of computational methods to identify novel compounds. 
One of those methods is docking of drug molecules with receptors [16]. 
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2.1 Tuberculosis (TB): 
Tuberculosis (TB) is a deadly infectious disease and is the leading cause of death worldwide, 
killing around 2 million people annually, primarily in developing countries. The World Health 
Organization (WHO) estimates that over one third of the world’s population is infected with TB 
with approximately 8 million new cases of infection diagnosed every year [1]. After human 
immunodeficiency virus (HIV)/AIDS, TB is the second most common cause of death due to an 
infectious disease, and current trends suggest that TB will still be among the 10 leading causes of 
global disease burden in the year 2020[2].TB incidence is also on the rise because of the 
correspondingly high HIV infection rates. These two diseases progress at faster rates in co-
infected individuals. The immune systems have been compromised by HIV/AIDS, so individuals 
fall victims to TB which takes opportunity of their weakened immune systems. There is a great 
interest in the scientific field to come up with a new drug(s) to combat TB. 
Tuberculosis is an airborne infectious disease caused by mycobacteria, mainly Mycobacterium 
tuberculosis (Mtb) [17]. It is caused by other mycobacteria also such as Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium canetti, and Mycobacterium microti, but these 
species are less common. These species infect other animals (e.g., cattle, Mycobacterium bovis; 
birds, Mycobacterium avium) but rarely infect humans. TB most commonly affects the lungs but 
can also affect many parts of the body such as the kidney, the lymph nodes, and the spine. 
2.1.1 Mycobacterium tuberculosis: 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is an obligate aerobe 
whose sole host is humans. The primary mode of transmission of Mtb is through the air in an 
aerosolized form, most commonly via a cough or sneeze [3]. Once in the terminal alveoli of the 
lungs, Mtb is phagocytized by host macrophages. In this early stage of infection, Mtb is able to 
replicate within non-activated macrophages [3]. However, the body subsequently mounts a cell-
mediated immune response to the growing mycobacteria, which includes the activation of 
macrophages with interferon-γ [4]. The cell-mediated immune response is sufficient 90-95% of 
the time in controlling the Mtb infection, but not completely eradicating the mycobacteria from 
the host [5]. 
                                                                                    
                    Fig1a: Transmission Electron Micrograph of Mtb                                                               
Ref:(http://www.wadsworth.org/databank/mycotubr.htm)  
The success of mycobacteria in producing disease relies entirely on its ability to utilize 
macrophages for its replication and more importantly, the maintenance of viability of host 
macrophages that sustain mycobacteria. M. tuberculosis has evolved several mechanisms to 
circumvent the hostile environment of the macrophage, its primary host cell. In spite of extensive 
research, our knowledge about the virulence factor(s) of M. tuberculosis is inadequate. A variety 
of mechanisms have been suggested to contribute towards the survival of mycobacteria within 
macrophages. These mechanisms include (i) inhibition of phagosome-lysosome fusion [12]; (ii) 
inhibition of phagosome acidification[13], (iii) recruitment and retention of tryptophan/aspartate 
containing coat protein on phagosomes to prevent their delivery to lysosomes [14]; and (iv) host 
induced expression of members of the PE-PGRS family of proteins[15]. 
2.1.2 Tuberculosis Causes: All cases of TB are passed from person to person via droplets. 
When someone with TB infection coughs, sneezes, or talks, tiny droplets of saliva or mucus are 
expelled into the air, which can be inhaled by another person. Once infectious particles reach the 
alveoli (small saclike structures in the air spaces in the lungs), another cell, called the 
macrophage, engulfs the TB bacteria. Then the bacteria are transmitted to the lymphatic system 
and bloodstream and spread to other organs occurs. The bacteria further multiply in organs that 
have high oxygen pressures, such as the upper lobes of the lungs, the kidneys, bone marrow, and 
meninges- the membrane-like coverings of the brain and spinal cord. When the bacteria cause 
clinically detectable disease, you have TB. People who have inhaled the TB bacteria, but in 
whom the disease is controlled, are referred to as infected. Their immune system has walled off 
the organism in an inflammatory focus known as a granuloma. They have no symptoms, 
frequently have a positive skin test for TB, yet cannot transmit the disease to others. This is 
referred to as latent tuberculosis infection or LTBI. 
2.1.3 Tuberculosis Symptoms: Symptoms of illness can not be noticed until the disease is quite 
advanced. Even then the symptoms -- loss of weight, loss of energy, poor appetite, fever, a 
productive cough, and night sweats -- might easily be blamed on another disease. Only about 
10% of people infected with M. tuberculosis ever develop tuberculosis disease. Many of those 
who suffer TB do so in the first few years following infection, but the bacillus may lie dormant 
in the body for decades.  Although most initial infections have no symptoms and people 
overcome them, they may develop fever, dry cough, and abnormalities that may be seen on a 
chest X-ray. This is called primary pulmonary tuberculosis. Pulmonary tuberculosis frequently 
goes away by itself, but in 50%-60% of cases, the disease can return. Tuberculous pleuritis may 
occur in 10% of people who have the lung disease from tuberculosis. The pleural disease occurs 
from the rupture of a diseased area into the pleural space, the space between the lung and the 
lining of the abdominal cavity. These people have a nonproductive cough, chest pain, and fever. 
The disease may go away and then come back at a later date.  In a minority of people with 
weakened immune systems, TB bacteria may spread through their blood to various parts of the 
body. This is called miliary tuberculosis and produces fever, weakness, loss of appetite, and 
weight loss. Cough and difficulty breathing are less common. About 15% of people may develop 
tuberculosis in an organ other than their lungs like lymph nodes, genitourinary tract, bone and 
joint sites, meninges, and the lining covering the outside of the gastrointestinal tract. About 25% 
of these people usually had known TB with inadequate treatment. 
2.2 Tuberculosis Treatment: Standard therapy for active TB consists of a six-month regimen. 
Prescribing doses twice a week helps assure compliance. The most common cause of treatment 
failure is people's failure to comply with the medical regimen. This may lead to the emergence of 
drug-resistant organisms. Medications should be taken as directed, even if the person is feeling 
better. Another important aspect of tuberculosis treatment is public health.  
2.2.1 Status of current tuberculosis drug therapy: 
Drugs available for the treatment of tuberculosis can be classified into two categories; first line 
drugs such as, isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB) etc., 
and second line drugs like para-amino salicylate (PAS), kanamycin, cycloserine (CS), 
ethionamide (ETA), amikacin, capreomycin, thiacetazone, fluoroquinolones etc. Current TB 
therapy, also known as DOTS (directly observed treatment, short-course) consists of an initial 
phase of treatment called intensive phase with 4 drugs, INH, RIF, PZA and EMB, for 2 months 
daily, followed by treatment with INH and RIF for another 4 months called continuation phase, 
three times a week. The whole treatment is abbreviated as 2HREZ/4HR3[22]. 
                            Table1: First Line of Drugs against tuberculosis 
First line of Drugs 
Intensive Phase Continuation Phase 
Drugs Duration Drugs Duration 
Rifampicin 
Isoniazid 
Pyrazinamide 
Ethambutol 
2 months Rifampicin 
Isoniazid 
 
 
4 months 
                                    
The targets of these drugs are varied. INH, inhibits synthesis of mycolic acid, a cell well 
component; PZA targets cell membrane whereas rifampin and streptomycin interferes with the 
initiation and streptomycin interferes with the initiation of RNA and protein synthesis 
respectively. EMB blocks biosynthesis of arabinogalactan, a major polysaccharide present in the 
mycobacterial cell wall and kanamycin and capreomycin, like streptomycin, inhibit protein 
synthesis through modification of ribosomal structures at the 16S rRNA. Cycloserine prevents 
the synthesis of peptidoglycan, a constituent of cell wall. 
                                    
               Fig2: Various pharmaceutical tuberculosis treatments and their actions. 
           Ref: (http://en.wikipedia.org/wiki/File:Tuberculosis-drugs-and-actions.jpg) 
2.2.2 Limitations of current drug therapy and need for new drug targets: 
      In the present scenario, due to the emergence of multi drug resistant tuberculosis (MDR-TB) 
and association between HIV and TB, DOTS is becoming rapidly ineffective in controlling 
tuberculosis. Recent reports indicate that, areas where there is a high incidence of MDR-TB, 
DOTS is failing to control the disease [18]. In such circumstances, the second line drugs are 
prescribed in combination with DOTS. However, this combination of drugs is very expensive, 
are less effective and thus has to be administered for a longer duration(e.g. p-amino salicylic 
acid), has significant side effects(e.g.,cycloserine) and some are unavailable in many developing 
countries(e.g. fluoroquinolones).                
                  Table2: Second Line of Drugs against tuberculosis                   
            Second line of Drugs 
         Old                     New 
Ethionamide  
Cycloserine 
Capreomycin 
Amikacyn   
Kanamycin 
PAS  
Thiocetazone 
Quinolones: ofloxacin, 
ciprofloxacin & sparfloxacin 
Macrolides: clarithromycin 
Clofazimine, Amoxycillin & 
Clavulanic acid 
 One major drawback of current TB therapy is that the drugs are administered for at least 6 
months. The length of therapy makes patient compliance difficult, and such patients become 
potent source of drug-resistant strains. The second major and serious problem of current therapy 
is that most of the TB drugs available today are ineffective against persistent bacilli, except for 
RIF and PZA. RIF is active against both actively growing and slow metabolizing non-growing 
bacilli, whereas PZA is active against semi-dormant non-growing bacilli [19]. However, there 
are still persistent bacterial populations that are not killed by any of the available TB drugs. 
Therefore, there is a need to design new drugs that are more active against slowly growing or 
non-growing persistent bacilli to treat the population at risk of developing active disease through 
reactivation. Secondly, it is important to achieve a shortened therapy schedule to encourage 
patient’s compliance and to slow down the development of drug resistance in mycobacteria. 
                          
       Fig3: Stages of mycobacterial infection-Activated and Latent Stage 
2.3 Genes involved in dormancy or persistence 
 Mycobacterium has the unique property of becoming persistent or dormant for very long 
periods. This stage of mycobacteria poses a significant problem for effective therapy as these 
persistent bacilli are resistant to most of the currently available drugs for the treatment of 
tuberculosis. The mechanism of mycobacterial persistence or dormancy is far from being 
understood. It is believed that during latent stage, mycobacterium utilises fatty acids and two 
carbon compounds via Glyoxylate shunt in TCA cycle to get the nutrition [38, 39]. The two 
enzymes of glyoxylate shunt, Isocitrate lyase (ICL) and Malate Synthase (MS), have been shown 
to be involved in the persistence of M.tuberculosis. Genes encoding for the two enzymes 
involved in Glyoxylate cycle are aceA & icl for isocitrate lyase and glcB for malate synthase. 
The interesting point is that these enzymes are not essential for the viability of tubercle bacilli in 
normal cultures or in hypoxic conditions, but are important for persistence of bacilli in mice.  
         It is well documented that the current drugs against TB were designed to attack 
M.tuberculosis during its active phase, however, the drugs have been ineffective when the 
bacteria is in its dormant stage—also known as the Non-Replicating Persistence phase. This is 
why an enzyme (protein) malate synthase is a focus of the study. This protein is a vital necessity 
for M.tuberculosis life sustenance during this dormant stage, therefore studying the structure and 
possible molecules that could inhibit the enzyme’s activities and survival of the bacteria are 
among the work that scientists are currently undertaking. During the bacteria’s dormant phase, it 
utilizes energy made by converting fatty acids to carbohydrates in what is known as the 
glyoxylate bypass flux. Basically the bacteria make a bypass of the nearly universal known 
metabolic pathway, the Krebs cycle, also known as citric acid cycle or tricarboxylic acid cycle 
(TCA). This pathway is made possible by a number of enzymes, and malate synthase just 
happens to be among these. So, the approach to interfere with the glyoxylate bypass by designing 
inhibitors to the enzyme is promising in the assessment of drug targets against the pathogen. 
  
 
 
 
     
                
 
 
                            Fig4: Glyoxylate Cycle: Bypass in TCA Cycle 
2.3.1 Glyoxylate Cycle:  
        The glyoxylate cycle, also called the glyoxylate shunt, is present in fungi, plants, and 
bacteria, but not in mammals. The cycle is essential for growth on two-carbon compounds such as 
ethanol and acetate, and plays an anaplerotic role in the provision of precursors for biosynthesis. 
The glyoxylate cycle is comprised of many of the same reactions as the TCA cycle, but it does not 
include the two decarboxylation reactions. As a result, two-carbon substrates, which enter the 
cycle as acetyl-CoA, can be converted to four-carbon compounds, which in turn can be further 
metabolized to create sugars and other essential organic compounds. Although several of the 
reactions of the glyoxylate and TCA cycle are identical, many of them are catalyzed by different 
isozymes in different cellular compartments. The glyoxylate cycle occurs in the peroxisome and 
cytoplasm, while the TCA cycle occurs in the mitochondria. Utilization of two-carbon 
compounds also requires the TCA cycle and gluconeogenesis, which are coordinately regulated 
with the glyoxylate cycle. The succinate provided by the glyoxylate cycle enters the TCA cycle 
where it is converted to malate; malate then reenters the cytoplasm where it is converted to 
oxaloacetate and eventually to glucose via gluconeogenesis. 
The glyoxylate cycle has two critical steps. In the first, isocitrate (six carbons) is hydrolyzed to 
succinate (four carbons) and glyoxylate (two carbons) by isocitrate lyase(ICL). In the second step, 
acetyl-CoA (two carbons) is condensed with glyoxylate to produce malate (four carbons) by 
malate synthase (MS). Thus, C2 compounds can replenish the intermediates of the TCA cycle via 
the glyoxylate cycle. The activation of this pathway represents the response of these 
microorganisms to nutrient starvation in the phagosome. 
2.3.2 Significance of Malate Synthase: 
        M. tuberculosis is an obligate aerobe (weakly Gram-positive mycobacterium) with a 
genome size of about 4 million base pairs, with 3959 genes. A single malate synthase gene called 
glcB (also referred to as aceB in M. tuberculosis CDC1551; MT1885; see www.tigr.org) has 
been identified in M. tuberculosis encoding a malate synthase G (MSG).  M.tuberculosis GlcB is 
an 80-kDa monomeric protein with 741 amino acid residues, which is homologous to malate 
synthase (AceB) of the Gram-positive bacterium Corynebacterium glutamicum (23) and MSG of 
the Gram-negative Escherichia coli. Malate synthase is one of the two enzymes of Glyoxylate 
Cycle which is essential for the persistence of bacteria. The structure of malate synthase is 
known having three domains. Domain I is 8α/8β TIM barrel consisting of residues 115–134 and 
266–557 shown in Fig4 with  α helices in cyan and β strands shown in blue. Domain II at the C 
terminus consists of residues 591–727, is mostly helical, and is shown in green. The β-rich 
domain III is inserted in the TIM barrel between 1 and β2 and is shown in orange. The N-
terminal 110 residues are shown in white. Glyoxylate is indicated in ball-and-stick representation 
sitting at the C-terminal end of the β-sheet. The Mg2+ ion sitting in the active site is shown in 
magenta. 
                   
Fig5: Ribbon representation of structure of malate synthase. 
         Malate synthase has been placed in its own superfamily called malate synthase G [24,25] 
(scop.mrc-lmb.cam.ac.uk/scop/). To date no other members of this fold specifically contain an 
insert of an all β domain in the barrel with an all  helical C-terminal domain. The closest fold is 
that of the phosphoenolpyruvate/pyruvate superfamily containing pyruvate kinase, which has an 
all β domain inserted at β loop 3 and a mixed /β C-terminal domain (scop.mrc-
lmb.cam.ac.uk/scop/).  
        The active site residues of malate synthase from M.tuberculosis have been identified. The 
active site is located at the interface of the TIM barrel and domain II, and a loop, which consists 
of residues 616–633, forms part of this interface. A glyoxylate molecule that was not included in 
the crystallization condition was found in the active site, as it was in E. coli GlcB (26). A Mg2+ 
ion required for activity is bound in a near perfect octahedral coordination by the carboxylate 
side chains of Glu-434, 2.1 Å away and OD1 of Asp-462 at 2.0 Å, one carboxylate oxygen (O3 
2.1 Å away) and one aldehyde oxygen (O1 2.5 Å away) of the substrate glyoxylate, and two 
water molecules 2.1 Å and 2.2 Å away, respectively (see Fig. 6). Glyoxylate binds via the 
aldehyde oxygen (O1) forming a hydrogen bond to NH1 of Arg-339, 3.1 Å away. O2 of 
glyoxylate is hydrogen bonded to the backbone NH group of 461 (2.9 Å), whereas O3 of the 
glyoxylate interacts with the backbone NH of residue 462 at 3.0 Å. Both Glu-434 and Asp-462, 
important in coordinating the Mg2+, and residue Arg-339, important in binding glyoxylate, are 
found to be conserved in all known malate synthase sequences of both the A and G types (Fig. 
5). 
 Fig6: Multiple Sequence alignment of malate synthases. Conserved residues are shown in 
green, and similar residues are shown in yellow. 
                                 
Fig7: Active site of the GlcB-glyoxylate binary complex. Mg
2+
 is held in an octahedral coordination by the 
carboxylate side chains of Glu-434 and Asp-462, one carboxylate oxygen, one aldehyde oxygen of 
glyoxylate- and two water molecules. 
2.4 Identification of active molecule: Why PKBA? 
          The inhibitory effect of Phenyl keto butanoic acid and its derivatives on malate synthase 
enzyme have been studied [27]. Also, PKBA derivatives are known to inhibit kynurenine 3-
hydroxylase and are used in treatment of inflammation. The progenitor inhibitor from the PKBA 
family was originally identified from a GlaxoSmithKline screen that tested all molecules within 
their chemical libraries that were similar in structure to reactants, products, or putative transition 
state compounds of MS. PKBA family derivatives share the same parent skeleton with malate 
(product) Of MS. 
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3.1 Visualization Tools 
3.1.1 Chimera-(Getting familiar with structure): 
 It helps us to fetch the structure either directly from the PDB site or through many other formats 
we have already stored, also one can try to localize the ligand that is in the active site and display 
the structure which is protein with the inhibitor. Identification of secondary structure can be 
done, as it can show and hide ribbons. One can observe the secondary structure motifs of the 
protein and also create a molecular surface around the protein, then color the surface according 
to different properties of the amino acids. Studying the protein-ligand interaction can be done by 
identifying the residues within 5.0Å, and then identify the residues involved in the binding and 
label the residue names and types. Chimera can also show the hydrogen bonds interaction 
between proteins and ligands. 
3.1.2 Energy minimization: 
Before energy calculations can be performed, it is necessary to correct structural inconsistencies, 
add hydrogen, and associate atoms with force field parameters. Clicking Minimize dismisses the 
dialog (unless the option to Keep dialog up after Minimize is checked) and may call Dock Prep 
to perform several tasks to prepare the structure(s). Dock Prep may in turn call Add H and Add 
Charge. Each of the tasks is a checkbox option that can be turned off independently if already 
done or deemed unnecessary. Minimize Structure energy-minimizes molecule models, optionally 
holding some atoms fixed. Minimization routines are provided by MMTK, which is included 
with Chimera. The Amber ff99 force field is used for standard residues, and Amber's 
Antechamber module (also included with Chimera) is used to assign parameters to nonstandard 
residues. 
 3.2 Docking Tools 
3.2.1 Autodock 4.0  
AutoDock is a suite of automated docking tools. It is designed to predict how small molecules, 
such as substrates or drug candidates, bind to a receptor of known 3D structure. It is used to 
perform computational molecular docking of small molecules to proteins, DNA, RNA and other 
important macromolecules, by treating the ligand and selected parts of the target as 
conformationally flexible. AutoDock actually consists of two main programs: AutoDock 
performs the docking of the ligand to a set of grids describing the target protein; AutoGrid pre-
calculates these grids. It uses a scoring function based on the AMBER force field, and estimates 
the free energy of binding of a ligand to its target. Novel hybrid global-local evolutionary 
algorithms are used to search the phase space of the ligand-macromolecule system.  
Autodock is the first program to model flexible ligands to proteins.  
There are 3 brands of search in Autodock. 
1. Global Search Algorithm: 
−  Simulated Annealing (Goodsell et al. 1990) 
−   SA (Morris et al. 1996) 
− Genetic Algorithm (Morris et al. 1998)  
2. Local Search Algorithm:  
                −    Solis & Wets (Morris et al. 1998)  
      3. Hybrid global-local search algorithm: which is most powerful 
– Lamarckian GA (Morris et al. 1998)  
The introduction of AutoDock 4 comprises three major improvements: 
1. The docking results are more accurate and reliable.  
2. It can optionally model flexibility in the target macromolecule.  
3. It enables AutoDock's use in evaluating protein-protein interactions. 
AutoDock 4 offers many new features and improvements over previous versions. The most 
significant is that it models flexible side chains in the protein. We can get both the 3D structure 
and the inhibition constants (Ki). Empirical free energy function estimates Ki (Std. dev. ~2 Kcal 
mol
-1
) 
Empirical free energy function (van-der Waals forces, Hydrogen Bonding, Electrostatics, 
Desolvation, Torsional) are used for SCORING. 
Binding energy=Intermolecular energy+Torsional energy  
∆Gbind = ∆Gvdw + ∆Gele.  + ∆GH-bond + ∆G desolv +∆Gtors  
 Here ∆G=change in free energy 
∆GvdW : 12-6 Lennard-Jones potential 
∆Gelec : Coulombic with Solmajer-dielectric 
∆Ghbond : 12-10 Potential with Goodford Directionality 
∆Gdesolv : Stouten Pairwise Atomic Solvation Parameters 
∆Gtors : Number of rotatable bonds  
3.2.2 GOLD: 
GOLD (Genetic Optimization for Ligand Docking) is a genetic algorithm for docking flexible 
ligands into protein binding sites. GOLD provides all the functionality required for docking 
ligands into protein binding sites from prepared input files. GOLD offers a choice of scoring 
functions, GoldScore, ChemScore, Astex Statistical Potential (ASP) and User Defined Score 
which allows users to modify an existing function or implement their own scoring function. 
The GOLD fitness function (Goldscore) is made up of four components: 
• protein-ligand hydrogen bond energy (external H-bond) 
• protein-ligand van der Waals (vdw) energy (external vdw) 
• ligand internal vdw energy (internal vdw) 
• ligand torsional strain energy (internal torsion) 
•Optionally, a fifth component, ligand intramolecular hydrogen bond energy (internal H-bond), 
may be added. output files will contain a single internal energy term S(int) which is the sum of 
the internal torsion and internal vdw terms. 
S(int)= internal torsion+ internal vdw 
The fitness score is taken as the negative of the sum of the component energy terms, so that 
larger fitness scores are better. If any constraints have been specified, then an additional 
constraint scoring contribution S(con) will be made to the final fitness score. Similarly, when 
docking covalently bound ligands a covalent term S(cov) will be present. 
The ChemScore function was trained by regression against measured affinity data. ChemScore 
estimates the total free energy change that occurs on ligand binding as: 
         ∆Gbind = ∆G0  + ∆GH-bond + ∆Gmetal + ∆Glipo +∆Grot 
The final ChemScore value is obtained by adding in a clash penalty and internal torsion terms, 
which militate against close contacts in docking and poor internal conformations. Covalent and 
constraint scores may also be included. 
Chemscore = ∆Gbinding + Pclash + cinternalPinternal + (ccovalentPcovalent +Pconstraint ) 
3.3 Molecular Modeling: 
Molecular modeling is a collective term that refers to theoretical methods and computational 
techniques to model or mimic the behavior of molecules. The techniques are used in the fields of 
computational chemistry, computational biology and materials science for studying molecular 
systems ranging from small chemical systems to large biological molecules and material 
assemblies. The simplest calculations can be performed by hand, but inevitably computers are 
required to perform molecular modeling of any reasonably sized system. The common feature of 
molecular modeling techniques is the atomistic level description of the molecular systems; the 
lowest level of information is individual atoms (or a small group of atoms). This is in contrast to 
quantum chemistry (also known as electronic structure calculations) where electrons are 
considered explicitly. The benefit of molecular modeling is that it reduces the complexity of the 
system, allowing many more particles (atoms) to be considered during simulations. 
3.3.1 Molecular Dynamics Simulation 
Although normally represented as static structures, molecules such as lysozyme are in fact 
dynamic. Most experimental properties, for example, measure a time average or an ensemble 
average over the range of possible configurations the molecule can adopt. One way to investigate 
the range of accessible configurations is to simulate the motions or dynamics of a molecule 
numerically. This can be done by computing a trajectory, a series of molecular configurations as 
a function of time, by the simultaneous integration of Newton's equations of motion: 
  
  dri(t)   =     vi(t)          (eqn. 1) 
    dt 
and 
  dvi(t)   =      Fi(t)         (eqn. 2) 
   dt                mi 
for all atoms (i = 1, 2 ,...,N) of the molecular system. The atomic coordinates, r, and the velocity, 
v, of atom, i, with mass, mi, thus become functions of time. The force Fi exerted on atom i by the 
other atoms in the system is given by the negative gradient of the potential energy function V 
which in turn depends on the coordinates of all N atoms in the system: 
 Fi(t)  =  -δV (r1(t),r2(t),…,rN(t))            (eqn. 3) 
                            δri(t) 
For small time steps δt, eqn. (2) can be approximated by 
  Vi(t+∆t/2) =  vi(t-∆t/2) + Fi(t) . ∆t        (eqn. 4) 
                                        mi 
and eqn. (1) likewise by 
ri(t+∆t) = ri(t) + vi(t+∆t/2)∆t    (eqn. 5) 
Eqns (4) and (5) form the so-called leap-frog scheme for integrating Newton's equations of 
motion. Typically a time step of 1 to 10 fs is used for molecular systems. Thus a 100 ps (10-10 
seconds) molecular dynamics simulation involves 105 to 104 integration steps. Even using the 
fastest computers only very rapid molecular processes can be simulated at an atomic level. As 
with any aspect of modeling, the accuracy of the predicted dynamics will depend on the validity 
of the underlying assumptions of the model. In this case the model is essentially defined by the 
force field that is used.  
Factors that govern the outcome of MD simulations are:  
i. choice of the degrees of freedom  
ii. force field parameters  
iii. treatment of non-bonded interactions  
iv. solvation effects  
v. boundary conditions  
vi. treatment of temperature and pressure  
vii. integration time step  
viii. starting configuration  
As with any aspect of modeling, the accuracy of the predicted dynamics will depend on the 
validity of the underlying assumptions of the model. In this case this is essentially defined by the 
model for the intermolecular interactions (or potential energy) used. That model is a 
mathematical function (force field) that describes how the value for the potential energy depends 
on the spatial arrangement of all the atoms. 
3.3.2 GROMACS (The MD Package): 
The following is designed to acquaint you with the general features of the molecular dynamics 
software package Gromacs. Gromacs is a widely used molecular dynamics simulation package 
developed at the University of Groningen. Information on Gromacs can be found at 
http://www.gromacs.org/.  
To run a simulation several things are needed:  
i. A file containing the coordinates for all atoms . 
ii. Information on the interactions (bond angles, charges, Van der Waals). 
iii. Parameters to control the simulation.  
The .pdb or .gro file contains the coordinates for all atoms and is the input structure file for MD 
simulation. The interactions are listed in the topology (.top) file and the input parameters are put 
into a .mdp file. To get an idea of the different file types processed by Gromacs, follow this link.  
The actual steps in an MD simulation are: 
i. Conversion of the pdb structure file to a Gromacs structure file, with the simultaneous 
generation of a descriptive topology file. & Energy minimization of the structure to 
release strain.  
ii. Running full simulations & Analyzing results. 
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4.1 Pharmacophore Analysis of Active Site Residues: 
By mutational analysis the functionally important residues that have been identified are Glu434, 
Arg339, Asp462, and Leu461. The active site residues were also visualized by generating 
pharmacophore by LigandScout2.0.  
                              
Fig8: Active Site Identification from Crystal Structure of Malate Synthase    complex with Malate 
by pharmacophore generation. 
The hydroxyl group present in malate is donating the hydrogen bond to Glu434.The ligand is 
accepting the hydrogen bond from Asp462,Arg339,Leu461. Blue line shows the metal(Mg2+) 
binding to the ligand. Red lines show the negative ionizable area.  
4.2 Dataset:  
30 non-peptide inhibitor molecules were designed based on PKBA backbone (Fig9). The 
designed inhibitors have the same parent skeleton as that of malate: the product of enzyme 
malate synthase. These molecules were designed based on Lipinski’s rule of five which was 
accessed from the server (http://www.scfbio-iitd.res.in/utility/LipinskiFilters.jsp). Lipinski’s rule 
of 5 helps in distinguishing between drug like and non drug like molecules. It predicts high 
probability of success or failure due to drug likeness for molecules complying with 2 or more of 
the following rules: 
• Molecular mass less than 500 Dalton. 
• High lipophilicity (expressed as LogP less than 5). 
• Less than 5 hydrogen bond donors. 
• Less than 10 hydrogen bond acceptors. 
• Molar refractivity should be between 40-130. 
Table3:  Designed Molecules passing the Lipinski’s rule of 5. 
Molecule Molecular 
Mass 
LogP H-Bond Donors H-Bond 
Acceptors 
Molar Refractivity 
1 194 -1.363 2 2 48.779 
2 192 1.826 3 0 52.023 
3 208 -0.496 3 1 53.894 
4 226 2.049 3 0 57.069 
5 222 1.460 4 0 58.225 
6 217 1.376 4 0 59.262 
7 238 0.664 3 1 43.074 
8 214 0.032 3 1 54.106 
9 222 0.155 3 1 57.914 
10 222 0.074 3 1 58.034 
11 224 -2.296 3 2 54.571 
12 222 -1.056 4 1 53.687 
13 222 -1.056 4 1 53.687 
14 220 0.184 5 0 52.803 
15 240 -2.590 3 3 56.235 
16 270 -1.939 4 4 58.679 
17 286 -2.872 4 4 64.451 
18 300 -2.566 5 3 69.339 
19 298 -1.963 5 2 72.412 
20 270 -2.576 3 4 62.636 
21 238 -1.906 3 2 59.188 
22 266 -1.370 3 2 68.782 
23 270 -2.576 3 4 62.636 
24 314 -2.259 6 2 74.227 
25 268 -3.634 4 3 61.393 
26 269 -2.017 6 2 60.712 
27 304 -1.983 5 3 63.598 
28 238 -1.987 3 2 59.308 
29 238 -1.987 3 2 59.308 
30 238 -1.987 3 2 59.308 
  
 Mycobacterium tuberculosis malate synthase (1N8I) was downloaded from Protein Data Bank 
(http://www.rcsb.org) (Fig4). 
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             Fig9: Chemical Structures of designed PKBA derivatives. 
4.3 Molecular Docking studies: 
4.3.1 Preparation of Ligands and Protein: 
Energy Minimization: The energy minimized files were generated for designed ligands in 
PRODRG server (http://davapc1.bioch.dundee.ac.uk/prodrg/)[30]. The experimental structure of 
M.tuberculosis malate synthase was extracted from the RCSB Protein data bank whose PDB 
code is 1N8I. There were two chains: Chain A & Chain B. Glyoxylate was found to bind with 
the chain A. Accordingly Chain B was removed. After removal of all hetero molecules except 
Mg2+ ion which was essential for malate synthase activity the protein structure was minimized. 
Whole process of energy minimization of protein was carried out in Chimera.  
Protein and Ligand Preparation in AutoDock: Since ligands are not peptides, Gasteiger charge 
was assigned and then non-polar hydrogens were merged [29]. The rigid roots were defined 
automatically rather manually for each compound considered. The Kollman charges were added 
to each atoms of the chain A taken [28].  
4.3.2 Grid Generation: 
The Grid box was centered on the active site residue Asp462. The binding site includes the 
catalytic center (Glu434, Asp462 and Arg339) and several subsites, as (Asp633, Glu273, 
Asp274, Leu461, Lys621 and Ser275).The spacing between the Grid points was 0.375 
angstroms. 
4.3.3 Docking (using Autodock4.0): 
The GA-LS (Lamarckian genetic algorithm) was chosen to search for the best conformers. 
During the docking process, the docking parameters were set to, Maximum Number of GA runs 
100, Population size of 150, Maximum number of evaluation 250000, Rate of Gene mutation 
0.02, and Rate of Crossover 0.8, for each Compound. The parameters were set using the software 
Autodock Tools available at (http://mgltools.scripps.edu/downloads ) which is made to associate 
with Autodock 4.0.The Calculations of Autogrid and Autodock were performed on Linux 
operating system having system Properties (Intel(R) Pentium(R) D CPU 2.80GHz, 2.0 GB of 
RAM). 
4.3.4 Docking (using GOLD): 
GOLD suite uses the Genetic Algorithm to search for the best conformers. During the docking 
process, the docking parameters were set to: Population Size-100, Selection pressure-1.1, 
Number of operations-100000, Number of islands-5, Niche size-2, Crossover frequency-95, 
Mutation frequency-95, Migration frequency-10. The calculations were performed on windows 
operating system having system Properties (Intel(R) Pentium(R) D CPU 2.80GHz, 2.0 GB of 
RAM). 
4.4 Evaluation of designed ligands by a flexible docking procedure  
4.4.1 AutoDock 4.0: 
At the end of the docking run, Autodock outputs a result which is the lowest energy 
conformation of the ligand, it found during that run. This conformation is a combination of 
translation, quaternion and Torsional angles and is characterized by intermolecular energy, 
internal energy and Torsional energy. The first two of these combined give the ‘Docking energy’ 
while the first and third give ‘Binding energy’ [31]. Autodock 4.0 also breaks down the total 
energy into Vander Waals (vdW) energy and an electrostatic energy for each atom. We used the 
overall lowest binding energy output by Autodock 4.0 and the inhibitory concentration (Ki), as 
the criterion for ranking. Therefore after ranking the ligands according to their lowest energies 
and lowest inhibitory concentration, the ligands were further carefully checked according to the 
factor such as ligands location, size of the ligand; to yield ligands with good steric 
complementarity. Furthermore their interactions with protein were analyzed by pharmacophore 
generation by Ligand Scout 2.0. The designed ligands were found to interact with active site 
residues.  
4.4.2 GOLD: 
At the end of the docking run, GOLD gives the output in terms of Fitness Score. The best docked 
molecule will have the highest Fitness Score i.e. the conformation of ligand having the lowest 
energy during the run. This conformation is a combination of protein-ligand hydrogen bond 
energy (external H-bond), protein-ligand van der Waals (vdw) energy (external vdw), ligand 
internal vdw energy (internal vdw), and ligand torsional strain energy (internal torsion). 
Optionally, a fifth component, ligand intramolecular hydrogen bond energy (internal H-bond), 
may also be added. Output files contain a single internal energy term S(int) which is the sum of 
the internal torsion and internal vdw terms. 
S(int)= internal torsion+ internal vdw 
 
4.5 Screening through ADME/Tox filter: 
All the designed ligands were made to pass through ADME/tox filters (http://mobyle.rpbs.univ-
paris-diderot.fr/cgi-bin/portal.py?form=admetox#). ADME/Tox, screens via simple filtering 
rules such as molecular weight, hydrogen donor number, hydrogen acceptor, polar surface area, 
logP or number of rotatable bonds or rigid bonds, toxic atoms filter, ring number, ring size, 
charge number, total charge, PSA. All parameters were set as default. 28 out of 30 designed 
ligands were found to pass ADME/tox filters with improved binding efficiency and steric 
complementarity. 
4.6 Molecular Dynamics Simulation Studies: 
Gromacs is a very powerful molecular simulation package. [32] Like other molecular 
mechanics/dynamics software packages, Gromacs uses an internal set of databases, which 
contain parameters for the amino acids, nucleic acids, cofactors, and some lipids that may be 
present in your PDB file. Gromacs does not know how to parameterize anything else in PDB file 
(i.e. the HETATM records). We must provide these missing parameters. The best docked 
molecule (results obtained from both GOLD and Autodock 4.0) was further analyzed for the 
stability of its interaction with the protein (malate synthase) using molecular dynamics 
simulation studies in Gromacs.  
 
4.6.1 Preparation of Ligand and Protein: 
A GMX topology file was prepared for the best docked molecule in Dundee PRODRG server 
(http://davapc1.bioch.dundee.ac.uk/programs/prodrg/). After putting drg.pdb coordinates into the 
empty text box on the webpage, Check the following options: 
Chirality                          Yes 
Full charges                     Yes 
Energy Minimization       No 
Click “Run PRODRG”. 
Download the Zipped Archive. 
DRGGMX.ITP file is used for building the topology for the drug. In addition,  
DRGFIN.GRO file is needed for building the coordinate file (*.GRO), or  
DRGPOH.PDB file can be used. The DRGGMX.ITP file was renamed to drg.itp. Our mal.pdb 
(1N8I) file was too crude to use with pdb2gmx. So it was minimized in Chimera for 100 steps.  
4.6.2 Simulation: 
The topology file for the protein molecule was generated. The dodecahedron water box was set 
having diameter 0.65.The dodecahedron water box saves around 30% of computational time in 
comparison to cubic box. The system was found to have a non-zero total charge. So it was 
neutralized by adding Na+ ions in the water box. Na+ ions were added by simply replacing the 
water molecules in the water box.  
The energy minimization of protein molecule was done. “Steep” algorithm was used for energy 
minimization and no constraints were set during the process. The other parameters set for 
minimization as: emtol 2000, emstep 0.01, nstcomm 1, ns_type grid, rlist 1, coulombtype PME, 
rcoulomb 1.0, and rvdw 1.4. No temperature coupling, pressure coupling was set and no velocity 
was generated during the process. The system was minimized to Fmax = 2000 in 1500 steps and 
the converged result came as:  
Steepest Descents converged to Fmax < 2000 in 675 steps 
Potential Energy    = -1.6725465e+06 
Maximum force     = 1.8101071e+03 on atom 6800 
Norm of force        = 1.3176494e+04 
A position restrained dynamics simulation was run to “soak” the water and the drug into the 
drug-enzyme complex. In this run, the atom positions of the protein are restrained to restrict their 
movement in the simulation (i.e. the atom positions are restrained not fixed!). The water and the 
drug are permitted to relax about the protein. The relaxation time of water is 10 ps. Therefore, a 
total of 30 ps dynamics run was used to perform the soak under coulombtype, PME which stands 
for “Particle Mesh Ewald” electrostatics. PME is the best method for computing long range 
electrostatics (gives more reliable energy estimates). [33,34] The all bonds option under 
constraints applies the Linear Constraint algorithm[35] for fixing all bond lengths (important to 
use this option when dt > 0.001 ps). Berendsen’s temperature and pressure coupling methods 
were used [36]. The reference temperature was set at 300 K and the velocity was also generated. 
The molecular dynamics simulation parameters were set for the Gromacs 87 force field, which 
we are using. For this run, we use the energygrps parameter to establish the groups for the 
energy output (the md.edr file). This will be important for use in for example linear interaction 
energy computations later on. 
The parameters which were set for the final md simulation are given in table4. 
Table4: Parameters for molecular dynamics simulation run 
cpp /usr/bin/cpp ; c-preprocessor 
dt 0.002           ; time step 
integrator md 
nsteps 5000000       ; number of steps (1ns) 
nstcomm 1                    ; reset c.o.m. motion 
nstxout 250                 ; write coords 
nstvout 1000          ; write velocities 
nstfout 10 
nstlog 10 
nstenergy 10              ; print energies 
nstlist 10              ; update pairlist 
ns_type grid            ; pairlist method 
coulombtype PME 
vdwtype Cut-off 
rlist 1.4              ; cut-off for ns 
rvdw_switch          0.8 
rvdw 1.4               ; cut-off for vdw 
rcoulomb_switch      0.8 
rcoulomb 1.4               ; cut-off for coulomb 
fourierspacing 0.12 
pme_order            6 
ewald_rtol           1e-5 
optimize_fft        Yes 
Tcoupl Berendsen    ; temperature bath (yes, no) 
ref_t 300 
tc-grps Protein  Non-Protein 
tau_t 0.1 
Pcoupl Berendsen 
pcoupltype Isotropic 
tau_p 0.5 
Compressibility 4.5e-5 
ref_p 1.0 
energygrps Protein SOL UNK Na 
gen_vel Yes 
gen_temp 300.0 
gen_seed 173529 
constraints all-bonds 
constraint-algorithm Shake 
unconstrained start Yes 
comm_grps Protein     Non-Protein 
comm_mode Linear   ; added to remove translation 
 
 
4.6.3 Analysis of md run: 
In analyzing a drug-enzyme complex, observations are key. You must ask the following 
questions: 
– Was the complex stable to the simulation conditions? (i.e. Did the drug remain in the 
active site pocket or did it fall out?) 
– Upon equilibration did the complex become more stable? Why? 
– What factors contributed to the stability? (hydrogen bonds; hydrophobic pockets; water 
bridges or other solvent interaction) 
The potential energy and kinetic energy of the system can be calculated to analyze the stability of 
system. Also, H-bond between drug and enzyme (protein) can be calculated. The most important 
is the calculation of rms value and obtain an RMSD plot of the protein backbone and drug 
throughout the simulation. Smaller rms value shows larger stability of enzyme-drug complex. 
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5.1 Docking Results in Autodock4.0: 
The docking results were ranked according to the ascent of the docking energies of the 100 
conformers for each of the ligands. The energy results were ranked according to the Binding 
Energy which included the Intermolecular Energy and the Torsional terms and inhibitory 
concentration (Ki) shown in Table 5. Compounds 28, 11, 3, 16 were found to be the best 
molecules. By generating pharmacophore in LigandScout with these molecules, it was found that 
these molecules were interacting quite well with the receptor protein. The best molecule is 
shown interacting with the receptor molecule in Fig10. These molecules were found to interact 
with the active site residues already identified in the receptor molecule which shows their 
probability of good binding. All of designed molecules were made to pass through ADME/tox 
filter. Out of 30 molecules, 28 were retrieved after the screening, which are non toxic with 
improved binding efficiency and steric complementarity. Also, an important observation was 
made by the docking studies of these designed molecules. The molecules were designed by 
making substitutions at different places in the phenyl ring and it was observed that meta 
substituted molecules were having better binding efficiency as can be seen from the binding 
energy(Table5). This meta effect can be observed in compounds 28, 29 and 30. Compound 28 is 
the methyl substituted molecule at meta position, Compound 29 has methyl group at ortho 
position and Compound 30 is para substituted molecule. Compound 28 has the best binding 
energy indicating the meta effect of substituted molecules on the inhibitor molecules. 
Table 5:  Binding Free Energies and inhibitory concentration of designed molecules. 
Compounds Binding Energy 
(Kcal/mol) 
   Ki (µmol)      Rank  ADME/Tox 
1 -5.24 144.49 27 No 
2 -6.25 26.12 23 No 
3 -7.52 3.08 3 P 
4 -5.98 41.22 25 P 
5 -6.46 18.44 20 P 
6 -6.81 10.21 10 P 
7 -6.39 20.74 21 P 
8 -6.65 13.33 15 P 
9 -6.88 9.02 9 P 
10 -6.47 17.99 19 P 
11 -7.54 2.96 2 P 
12 - - - P 
13 -6.92 8.45 7 P 
14 -6.9 8.69 8 P 
15 -6.61 14.38 16 P 
16 -7.35 4.1 4 P 
17 -6.49 17.34 18 P 
18 -5.95 43.71 26 P 
19 -6.75 11.24 12 P 
20 -7.18 5.41 5 P 
21 -6.15 31.1 24 P 
22 -6.78 10.8 11 P 
23 - - - P 
24 - - - P 
25 -6.34 22.68 22 P 
26 -6.67 12.81 14 P 
27 -6.59 14.86 17 P 
28 -7.79 1.95 1 P 
29 -6.69 12.52 13 P 
30 -7.12 6.0 6 P 
                           
                                  
   Fig10: Binding of Ligand with Active Site Residues shown by Pharmacophore Generation. 
 
5.2 Docking Results in GOLD: 
The docking results are ranked according to the ascent of the Fitness Function (Gold Score) for 
each of the ligands. The energy results were ranked according to the Fitness Function which 
includes the H-bond energy, Vander Waals energy and torsion energy shown in Table 6. 
Compounds 27, 28, 11, 12, 13, 16 were found to be the best molecules. The interaction was 
studied in GOLD and it was found that these molecules were interacting quite well with the 
receptor protein and known active site residues. The meta effect of substituted molecules was 
also observed from the docking studies in GOLD. It can be observed from Table 6, Compound 
28 (meta substituted) has larger Fitness Function than Compound 29 (ortho substituted) and 
Compound 30 (para substituted).  
 
Table 6:  Binding Free Energies of designed molecules in GOLD. 
Compounds               Fitness Function (Gold Score) 
      1 17.9401, 14.6939, 13.0875, 11.7236, 10.8979 
      2 43.77, 46.32, 43.40, 45.62 
      3 38.82, 33.46, 34.47, 38.02, 47.09, 47.25, 39.11, 39.89,45.83 
      4 48.73, 47.94, 48.54 
      5 42.61, 43.51, 49.77, 49.32 
      6 - 
      7 48.02, 40.71, 39.97, 45.34, 32.27, 36.11, 42.70 
      8 44.68, 46.05, 38.27 
      9 50.62, 49.39, 45.85, 47.53, 43.62, 48.35, 48.62, 47.90, 45.03, 46.93 
     10 41.86, 43.01, 38.97, 37.89, 39.92, 40.14, 38.59, 38.56, 41.42, 37.77 
     11 49.19, 49.53, 48.15 
    12 52.44, 52.61, 52.60 
    13 50.70, 51.11, 49.23 
    14 30.85, 32.31, 32.37 
    15 44.41, 40.82, 44.59, 47.70 
    16 53.25, 48.53, 50.88, 47.29, 49.65 
    17 29.72, 34.34, 28.88, 30.44 
     18 24.76, 25.64, 22.0 
     19 28.05, 26.07, 29.16 
     20 25.93, 26.99, 27.87 
     21 37.23, 43.34, 39.57, 42.46, 43.62, 39.63, 41.69, 41.80, 42.56, 45.21 
    22 29.47, 29.24, 25.53 
    23 27.33, 27.71, 27.28 
    24 14.65, 10.94, 8.38 
    25 37.19, 36.42, 38.59 
    26 41.23, 40.91, 40.38, 43.66, 43.54, 40.47, 42.43 
    27 56.16, 53.99, 48.74 
    28 49.75, 46.17, 50.56 
    29 40.22, 46.02, 49.43 
    30 31.81, 34.09, 39.75, 36.76, 39.52, 38.71, 43.11, 42.22, 39.53, 39.11 
 
5.3 Molecular dynamics simulation   
The complex of receptor protein with the best molecule (Compound27) obtained from docking 
studies was studied by molecular dynamics simulation in a water box model for 1.3 ns. Water 
molecules were initially equilibrated for 50 ns. An average structure obtained from 1100 ps to 
1300 ps was energy minimized under conjugated gradient and periodic boundary condition. MD 
simulations solve Newton’s equations of motion for a system of N interacting atoms. The 
equations are solved simultaneously in small time steps. The system is followed for some time, 
taking care that the temperature and pressure remain at the required values, and the coordinates 
are written to an output file at regular intervals. The coordinates as a function of time represent a 
trajectory of the system. After initial changes, the system will usually reach an equilibrium state. 
By averaging over an equilibrium trajectory many macroscopic properties can be extracted from 
the output file as in this md simulation run, the dynamics behavior and structural change of the 
receptor was analyzed by calculating the RMSD value for structural movement and change in the 
elements of secondary structure of the protein-ligand complex during the MD simulation. The 
structure change and stability of protein-ligand complex in water model was evaluated during 1.3 
ns MD simulation using GROMACS 3.3.1. This structure change and stability of protein-ligand 
complex was evaluated by calculating the potential energy output of complex as well as the 
RMSD of the backbone and drug molecule. The potential energy output of complex was 
analyzed and it was observed that the potential energy of the complex attains stability after 
sometime and a plateau was observed at 1.54 KJ/mol after 200ps (Fig11). Fairly low potential 
energy (1.54 KJ/mol) shows high stability of the protein-ligand complex and increases its 
chances to be drug like candidates. 
                                                                          
             
Fig 11: Potential energy graph of molecular dynamics simulation of protein –ligand complex during 1.3 ns 
using GROMACS 3.3.1 
        Potential energy of protein-ligand complex lies in range -1.54e+06 to -1.545e+06 and 
reaches a constant level after 250 ps. 
        The H-bond between drug molecule and enzyme were analyzed and after calculating the 
average of all H-bond candidates total 3.305 H-bonds were observed between ligand and 
receptor molecule. 
        The RMSD plots of protein backbone and the drug were obtained separately (Fig12 & 
Fig13 respectively). The backbone RMSD indicates that the rigid protein structure equilibrates 
rather quickly in this simulation (after 20 ps). The drug does not equilibrate until after 30 ps. The 
RMSD for the drug is more variable indicative of its mobility within the binding pocket. After 
observing RMSD plot of backbone given in Fig 12, it can be seen that RMSD attains stability 
after 750 ps and a plateau region was observed. While, RMSD plot of drug as observed in Fig 13 
is more variable throughout the run which shows it mobility in the binding pocket of receptor 
molecule. Also, after 250 ps run RMSD drops drastically from 4 A◦ to 2 A◦.       
                      
Fig 12: Plot showing the RMSD deviation of solvated protein back bone during 1.3 ns using GROMACS 
3.3.1 
                     
Fig 13: Plot showing the RMSD deviation of ligand in the solvated protein during 1.3 ns using GROMACS 
3.3.1 
     The average structure of protein-ligand complex was computed based upon the equilibration 
of drug for last 200 ps i.e. from 1100 ps to 1300 ps. The average structure computed was 
visualized in Pymol. It can be seen having interaction with the active site residues of receptor 
molecule as shown in Fig14. The average structure of protein-ligand complex can also be viewed 
in water box shown in mesh view (Fig 15). 
 
                             
Fig14: Average structure of protein-ligand complex during last 200 ps simulation run in solvated 
condition. 
 
                  
Fig 15: Average structure of protein-ligand complex during last 200 ps simulation in water box (mesh 
view). 
  The RMSD close to 1.0 A◦  (for backbone) and 2.0 A◦  (for drug molecule) and fairly low 
potential energy from -1.54e+06 KJ/mol to -1.545e+06 KJ/mol shows high stability of protein-
ligand complex shows the likeliness of ligand molecule to be drug like candidates.  
 
 
6. Conclusion: 
The Mtb persistence enzyme, malate synthase and its interaction with different inhibitors has 
been studied with various computational approaches. These studies were initiated because of 
attractiveness of Mtb Malate Synthase as a potentially novel anti-tubercular drug target. The 
enzyme Malate Synthase is not found in mammals as well as attempts to knockout this enzyme 
from Mtb have been unsuccessful, indicating its possible essential role in Mtb. The discovery of 
a potent inhibitor against Malate Synthase would help to validate the essentiality of protein. In 
this work, 30 inhibitor molecules of malate synthase were designed based on Lipinski’s rule of 5 
having Phenyl keto butanoic acid (PKBA) backbone. The interaction of these molecules was 
studied by  molecular docking study, by comparison of Scoring function in approximate order of 
ligand size, order of affinity thereby setting up the binding preferences for the derivatives of 
PKBA towards the binding site of malate synthase. The top molecules in Autodock and GOLD 
based on scoring function were identified whose energy value obtained is: Compound3 (-7.52), 
Compound11 (-7.54), Compound28 (-7.79), Compound16 (-7.35). These molecules were also 
passing the ADME/tox filter which shows the non-toxicity of these compounds and their 
likeliness to be drug like candidates. Also the substitution at meta position in phenyl ring, 
seemed to play a pivotal role in binding and could be further inferred that this could be a better 
position in substituting the phenyl ring in PKBA derivatives targeted against malate synthase. 
Further we have tried to look for the stability of the interaction of the best molecule (concluded 
from docking studies) by molecular dynamics simulation studies in water model.  The rmsd of 
less than 0.5Aο shows the highly stable protein-ligand complex i.e. a very strong interaction 
between best molecule and receptor molecule. All these results provide useful insight for the 
development of potential inhibitors against malate synthase enzyme. This computational 
approach like docking and molecular dynamics simulation is found to be helpful in designing 
new drugs against tuberculosis targeting Malate Synthase. In addition, to combat with the 
infection of deadly bacteria, the approach that is adopted in this work is versatile one which can 
combat with multi drug resistance property of the deadly bacteria.  
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